Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the fourth quarter of fiscal 2014 and full year fiscal 2014, both of which ended September 26, 2014.
Net sales were $789.3 million for the fourth quarter of fiscal 2014 compared with $545.2 million reported in the fourth quarter of fiscal 2013, an increase of 44.8%. Strong net sales were driven by the inclusion and performance of H.P. Acthar Gel (Acthar) repository corticotropin injection and OFIRMEV (acetaminophen) injection, acquired in August 2014 and March 2014, respectively, and continuing strength in its base Specialty Controlled Substance Generics portfolio.
Help employers find you! Check out all the jobs and post your resume.
